Clinical trials
Disease trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
434 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 3 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 7 |
| 2010 | 7 |
| 2011 | 11 |
| 2012 | 15 |
| 2013 | 11 |
| 2014 | 8 |
| 2015 | 20 |
| 2016 | 28 |
| 2017 | 41 |
| 2018 | 33 |
| 2019 | 30 |
| 2020 | 33 |
| 2021 | 44 |
| 2022 | 39 |
| 2023 | 54 |
| 2024 | 31 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 434 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 6 |
| Assistance Publique - Hôpitaux de Paris | 5 |
| First Affiliated Hospital Xi'an Jiaotong University | 5 |
| Peking Union Medical College Hospital | 5 |
| RenJi Hospital | 5 |
| Cairo University | 4 |
| Central South University | 4 |
| Changhai Hospital | 4 |
| Fudan University | 4 |
| Hospices Civils de Lyon | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease | 434 |
| Lung Neoplasms | 16 |
| Breast Neoplasms | 13 |
| Neoplasms | 11 |
| Prostatic Neoplasms | 11 |
| Pneumonia | 9 |
| COVID-19 | 8 |
| Colorectal Neoplasms | 7 |
| Sepsis | 7 |
| Tuberculosis | 7 |
Trials
Showing 1 to 25 of 434. Each trial links to its page on Pharma Observatory.
334 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.